ABVC Biopharma Inc
ABVC3.070USD
+0.320+11.64%
Horário de mercado （ET）Cotações atrasadas em 15 min
47.21MValor de mercado
PerdaP/L TTM
Mais detalhes de ABVC Biopharma Inc Empresa
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.
Informações da empresa
Código da empresaABVC
Nome da EmpresaABVC Biopharma Inc
Data de listagemNov 09, 2004
CEODr. Uttam Yashwant Patil
Número de funcionários16
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 09
Endereço44370 Old Warm Springs Blvd
CidadeFREMONT
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94538-6148
Telefone15106680881
Sitehttps://abvcpharma.com/
Código da empresaABVC
Data de listagemNov 09, 2004
CEODr. Uttam Yashwant Patil
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Shuling Jiang
Ms. Shuling Jiang
Director
Director
1.00M
+3.82%
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Chief Scientific Officer, Chief Strategy Officer, Director
Chief Scientific Officer, Chief Strategy Officer, Director
375.99K
-11.15%
Mr. Eugene Jiang
Mr. Eugene Jiang
Chairman of the Board, Chief Business Officer
Chairman of the Board, Chief Business Officer
131.16K
--
Mr. Yoshinobu Odaira
Mr. Yoshinobu Odaira
Independent Director
Independent Director
57.76K
--
Dr. Chang-Jen Jiang, M.D.
Dr. Chang-Jen Jiang, M.D.
Director
Director
42.03K
-0.12%
Dr. Tsang Ming Jiang, Ph.D.
Dr. Tsang Ming Jiang, Ph.D.
Director
Director
41.99K
--
Ms. Yen-Hsin Chou
Ms. Yen-Hsin Chou
Independent Director
Independent Director
41.96K
--
Ms. Norimi Sakamoto
Ms. Norimi Sakamoto
Independent Director
Independent Director
41.85K
--
Ms. Hsin-Hui Miao
Ms. Hsin-Hui Miao
Independent Director
Independent Director
41.51K
-13.66%
Mr. Yu- Min (Francis) Chung
Mr. Yu- Min (Francis) Chung
Independent Director
Independent Director
41.39K
-1.33%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Shuling Jiang
Ms. Shuling Jiang
Director
Director
1.00M
+3.82%
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Chief Scientific Officer, Chief Strategy Officer, Director
Chief Scientific Officer, Chief Strategy Officer, Director
375.99K
-11.15%
Mr. Eugene Jiang
Mr. Eugene Jiang
Chairman of the Board, Chief Business Officer
Chairman of the Board, Chief Business Officer
131.16K
--
Mr. Yoshinobu Odaira
Mr. Yoshinobu Odaira
Independent Director
Independent Director
57.76K
--
Dr. Chang-Jen Jiang, M.D.
Dr. Chang-Jen Jiang, M.D.
Director
Director
42.03K
-0.12%
Dr. Tsang Ming Jiang, Ph.D.
Dr. Tsang Ming Jiang, Ph.D.
Director
Director
41.99K
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Jiang (Shuling)
5.98%
YuanGene, Corp
4.95%
Jiang (Tsung-Shann)
2.24%
Jiang (Eugene)
0.78%
Geode Capital Management, L.L.C.
0.62%
Other
85.43%
Investidores
Investidores
Proporção
Jiang (Shuling)
5.98%
YuanGene, Corp
4.95%
Jiang (Tsung-Shann)
2.24%
Jiang (Eugene)
0.78%
Geode Capital Management, L.L.C.
0.62%
Other
85.43%
Tipos de investidores
Investidores
Proporção
Individual Investor
11.52%
Corporation
4.95%
Investment Advisor
1.02%
Investment Advisor/Hedge Fund
0.81%
Venture Capital
0.36%
Hedge Fund
0.08%
Other
81.25%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
34
3.14M
18.75%
-459.62K
2025Q1
36
3.18M
25.48%
-443.49K
2024Q4
37
3.35M
25.84%
-140.63K
2024Q3
38
3.28M
25.33%
-177.84K
2024Q2
39
3.21M
27.30%
-361.06K
2024Q1
37
3.25M
30.84%
+1.04M
2023Q4
37
1.92M
24.18%
+3.24K
2023Q3
39
1.80M
52.80%
+194.05K
2023Q2
37
1.48M
44.76%
-133.59K
2023Q1
36
1.48M
44.98%
+2.69K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Jiang (Shuling)
1.00M
5.98%
+36.89K
+3.82%
Apr 28, 2025
YuanGene, Corp
829.70K
4.95%
--
--
May 27, 2025
Jiang (Tsung-Shann)
375.99K
2.24%
-47.17K
-11.15%
Apr 28, 2025
Jiang (Eugene)
131.16K
0.78%
--
--
May 27, 2025
Geode Capital Management, L.L.C.
104.48K
0.62%
+25.20K
+31.78%
Mar 31, 2025
The Lind Partners, LLC
94.99K
0.57%
-105.06K
-52.52%
Dec 31, 2024
Patil (Uttam)
72.43K
0.43%
--
--
Apr 28, 2025
XTX Markets LLC
60.44K
0.36%
+26.03K
+75.67%
Mar 31, 2025
Odaira (Yoshinobu)
57.76K
0.34%
--
--
Apr 28, 2025
The Vanguard Group, Inc.
46.95K
0.28%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Data
Tipo
Proporção
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
Jul 24, 2023
Merger
10<1
